

Name of the Issue: Mankind Pharma Limited	
1	Type of Issue Initial Public Offer
2	Issue Size (Rs. Mn) 43,263.55*
<i>*Source: Prospectus dated April 28, 2023</i>	
3	Grade of issue along with name of the rating agency
	Name NA
	Grade NA

4 Subscription Level (Number of times) 15.4631*

** excluding Anchor Investor Portion and after removing multiple and duplicate bids*

Source: Minutes for basis of allotment dated May 03, 2023

5 QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges

Particulars	%
(i) On Allotment **	5.28%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (June 30, 2023)	4.18%
(iii) at the end of 1st FY (March 31, 2024)	21.01%
(iv) at the end of 2nd FY (March 31, 2025)	24.40%
(v) at the end of 3rd FY (March 31, 2026)	24.82%

***Basis of Allotment (excluding pre-issue QIB holding)*

6 Financials of the issuer

Rs. in Crores

Parameters	1st FY (March 31, 2024)	2nd FY (March 31, 2025)	3rd FY (March 31, 2026)
Income from operations	10,334.77	12,207.44	14,277.64
Net Profit/(Loss) for the period	1,941.77	2,060.59	1,938.10
Paid-up equity share capital	40.06	41.26	41.28
Reserves excluding revaluation reserves*	9,323.03	14,291.30	16,300.34

**Other Equity*

7 Trading Status

The equity shares of Mankind Pharma Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")

The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2024)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2025)	Frequently Traded
(iii) at the end of 3rd FY (March 31, 2026)	Frequently Traded

8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2024)	Mr. Ramesh Juneja	Re-appointed as Chairman and Wholetime Director
	Mr. Ramesh Juneja	Re-appointed as Vice Chairman and Managing Director
	Mr. Sheetal Arora	Re-appointed as Whole-time Director and Chief Executive Officer
(ii) at the end of 2nd FY (March 31, 2025)	Mr. Surendra Lunia	Cessation - Independent Director
(iii) at the end of 3rd FY (March 31, 2026)	Mr. Satish Kumar Sharma	Appointment - Executive Director

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable as 100% OFS
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds	Not applicable
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	Not applicable
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	Not applicable

12 Pricing Data

Designated Stock Exchange	NSE
Issue Price (Rs.)	1,080.00
Listing Date	May 09, 2023

Price parameters	At close of listing day- May 09, 2023	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day	As at the end of the 1st FY after the listing of the issue (31st March, 2024)		
				Closing price	High	Low
Market Price (Rs.)	1,430.00	1,486.2	1,803.5	2,300.8	2,336.4	1,322.7
Nifty 50*	18,265.95	18,726.4	19,597.3	22,326.9	22,493.6	17,398.1

Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March, 2025)			As at the end of the 3rd FY after the listing of the issue (31st March, 2026)		
	Closing price	High	Low	Closing price	High	Low
Market Price (Rs.)	2,424.75	3,054.80	1,901.05	2,005.80	2,696.50	1,927.40
Nifty 50*	23,519.35	26,277.35	21,281.45	22,331.40	26,328.55	22,161.60

* Being index of NSE, the designated stock exchange
High and Low based on Closing prices

13 Basis for Issue Price

Accounting ratio	Face Value per share (Rs.)	As disclosed in offer document*	At the end of 1st FY (March 31,2024)	At the end of 2nd FY (March 31,2025)	At the end of 3rd FY (March 31,2026)	
EPS (Diluted)	Company					
	<i>Consolidated</i>	1	35.78	47.68	49.20	46.35
	Peer Group:					
	<i>Sun Pharmaceuticals Industries Limited</i>	1	13.60	39.9	45.60	47.80
	<i>Cipla Limited</i>	2	31.17	51.01	65.24	48.00
	<i>Zydus Lifesciences Limited</i>	1	43.83	38.14	44.97	50.09
	<i>Torrent Pharmaceutical Limited</i>	5	22.97	48.94	55.79	63.90
	<i>Alkem Laboratories</i>	2	137.63	150.19	181.11	192.51
	<i>JB Chemicals & Pharmaceuticals Limited</i>	2	49.82	34.85	41.16	44.45
	<i>Eris Lifesciences Limited</i>	1	29.88	28.79	25.68	45.26
	<i>Ipca Laboratories Limited</i>	2	34.85	21.57	29.16	44.98
	<i>Abbott India Limited</i>	10	375.86	565.28	665.62	730.36
	<i>Glaxosmithkline Pharmaceuticals Limited</i>	10	100.04	34.83	54.52	60.11
	<i>Dabur India Limited</i>	1	9.81	10.38	13.53	10.66
	<i>Procter & Gamble Health Limited</i>	10	116.00	Not Available	110.97	196.94
	<i>Zydus Wellness Limited</i>	10	48.54	41.94	54.52	6.20
	Industry Avg		78.00	88.82	103.31	118.56
P/E	Company					
	<i>Consolidated</i>	1	30.18	48.25	49.00	43.36
	Peer Group:					
	<i>Sun Pharmaceuticals Industries Limited</i>	1	71.54	40.62	38.06	36.76
	<i>Cipla Limited</i>	2	28.18	29.35	22.73	25.50
	<i>Zydus Lifesciences Limited</i>	1	10.95	26.41	17.09	17.39
	<i>Torrent Pharmaceutical Limited</i>	5	66.25	53.14	58.14	66.02
	<i>Alkem Laboratories</i>	2	23.03	32.90	26.82	27.53
	<i>JB Chemicals & Pharmaceuticals Limited</i>	2	39.48	47.36	41.83	46.44
	<i>Eris Lifesciences Limited</i>	1	19.1	29.29	247.85	28.66
	<i>Ipca Laboratories Limited</i>	2	22.38	57.37	51.48	35.60
	<i>Abbott India Limited</i>	10	56.19	47.98	46.17	35.48
	<i>Glaxosmithkline Pharmaceuticals Limited</i>	10	57.03	55.89	52.78	37.98
	<i>Dabur India Limited</i>	1	54.55	50.40	37.44	38.50
	<i>Procter & Gamble Health Limited</i>	10	42.27	Not Available	46.34	24.37
	<i>Zydus Wellness Limited</i>	10	31.11	35.18	30.66	68.77
	Industry Avg		40.16	42.16	82.46	37.62

	Company					
	<i>Consolidated</i>	1	23.29%	20.74%	13.70%	11.89%
	Peer Group:					
	<i>Sun Pharmaceuticals Industries Limited</i>	1	6.82%	15.04%	13.09%	13.84%
	<i>Cipla Limited</i>	2	12.08%	15.55%	16.84%	11.24%
	<i>Zydus Lifesciences Limited</i>	1	26.40%	19.46%	27.25%	18.54%
	<i>Torrent Pharmaceutical Limited</i>	5	13.06%	24.15%	24.87%	25.49%
	<i>Alkem Laboratories</i>	2	19.05%	17.57%	18.48%	17.03%
RoNW	<i>JB Chemicals & Pharmaceuticals Limited</i>	2	18.06%	18.90%	19.35%	17.06%
	<i>Eris Lifesciences Limited</i>	1	21.28%	15.35%	3.07%	16.59%
	<i>Ipca Laboratories Limited</i>	2	16.10%	8.36%	8.50%	14.15%
	<i>Abbott India Limited</i>	10	28.32%	32.48%	33.41%	32.51%
	<i>Glaxosmithkline Pharmaceuticals Limited</i>	10	63.64%	33.19%	47.54	45.69%
	<i>Dabur India Limited</i>	1	20.75%	18.36%	16.11%	16.36%
	<i>Procter & Gamble Health Limited</i>	10	31.23%	Not Available	34.30%	62.32%
	<i>Zydus Wellness Limited</i>	10	6.38%	4.98%	0.76%	3.38%
	Industry Avg		21.78%	18.62%	18.00%	22.63%
	Company					
	<i>Consolidated</i>	10	31.76	2.34	355.34	394.87
	Peer Group:					
	<i>Sun Pharmaceuticals Industries Limited</i>	1	200.10	265.35	227.98	348.31
	<i>Cipla Limited</i>	2	258.32	330.78	193.71	426.24
	<i>Zydus Lifesciences Limited</i>	1	166.05	197.07	105.95	269.50
	<i>Torrent Pharmaceutical Limited</i>	5	175.89	202.58	22.40	247.86
	<i>Alkem Laboratories</i>	2	722.44	862.46	1,002.33	1,156.01
NAV per share	<i>JB Chemicals & Pharmaceuticals Limited</i>	2	240.83	188.37	217.46	258.98
	<i>Eris Lifesciences Limited</i>	1	140.39	190.12	184.64	281.78
	<i>Ipca Laboratories Limited</i>	2	216.47	249.59	220.50	317.85
	<i>Abbott India Limited</i>	10	1,327.00	1,740.71	199.21	2,246.68
	<i>Glaxosmithkline Pharmaceuticals Limited</i>	10	157.19	104.93	1,151.85	133.84
	<i>Dabur India Limited</i>	1	47.41	55.68	6.09	64.38
	<i>Procter & Gamble Health Limited</i>	10	371.39	Not Available	3,234.82	315.99
	<i>Zydus Wellness Limited</i>	10	761.26	841.95	891.31	183.21
	Industry Avg		368.06	435.80	728.76	480.82

Notes

* Sourced from Prospectus dated April 28, 2023.

14 Any other material information

For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com